Head and Neck Cancer
Conditions
Interventions
additional diagnostic scans
- 4 x FDG-PET/CT
- 4 x MRI
- 3 x HX4-PET/CT
Sponsors
Antoni van Leeuwenhoek Ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Histologic biopsy confirmed SCC oral cavity, oropharynx, hypopharynx, and larynx - HPV negative tumors - Largest tumor diameter at least 3 cm (primary tumor) - Scheduled for concurrent chemoradiotherapy or definitive external beam radiotherapy (DAHANCA schedule and normal fractionation are both applicable)
Exclusion criteria
Exclusion criteria: - SCC of the nasopharynx, nasal cavity, paranasal sinuses, salivary gland and thyroid gland - Expected failure from follow-up - Patients who are not expected to participate in at least 2 out of 3 imaging modalities (MRI, HX4-PET and FDG-PET) - Pregnancy or lactation - Patients (M/F) with reproductive potential not implementing adequate contraceptives measures at least 14 days before the first study procedure - Prior surgery, radiotherapy or chemotherapy for this tumor - Previous malignancies within the last 2 years except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determining the Ktrans, ADC, FDG-PET SUV en HX4-PET SUV signal changes during radiotherapy. Calculating the differentiating abilities between patients with and without a recurrence of these signal changes | — |
Secondary
| Measure | Time frame |
|---|---|
| Determine the correlation between the average signal changes during treatment of the different modalities. Determine the signal heterogeneity within the treatment and the heterogeneity differences between patients. Determine the prognostic value of the change in tumor volume. | — |
Countries
Netherlands
Outcome results
None listed